An interventional study of Intercostal nerve cryoablation and Levobupivacaine in Postoperative Pain After Thoracic Surgery and Lung Cancer (Suspected or Confirmed), sponsored by University Medical Centre Maribor. Enrolling by invitation at 1 site in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University Medical Centre Maribor · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lung Neoplasms with a site in Slovenia — 2 open to participants now, 2 under way, none of them phase 3. Lung Neoplasms · Slovenia.
Among the 12 studies in Lung Neoplasms with a site in Slovenia, this one is the only one that started in 2028, is one of 4 with no phase, and was the 12th registered.
5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →2 of the 12 studies in Lung Neoplasms with a site in Slovenia are open now. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Slovenia, Denmark, Georgia and 1 more country
Ages 18+
A study can be open while its sites in Slovenia have not opened yet or have stopped. Only those recruiting at a site in Slovenia →
Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 4
First in 1995; this study’s year is marked. 1 started in 2028.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.
Median enrollment 95 across the 9 interventional studies, 33 across the 3 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
University Medical Centre Maribor is the lead sponsor of 38 studies on the registry; 10 are open to participants now.
University Medical Centre Maribor has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Lung Neoplasms with a site in Slovenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07627022University Hospital Schleswig-HolsteinImpact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer | 2027-02-15 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Lung Neoplasms with a site in Slovenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find out whether adding intercostal nerve cryoablation to intercostal nerve blocks with levobupivacaine improves pain relief after minimally invasive surgery for lung cancer. Both treatments target nerves between the ribs. Levobupivacaine is a local anesthetic that temporarily blocks pain signals. Cryoablation uses very low temperatures to temporarily interrupt nerve function and may provide longer-lasting pain relief.
The study will include 80 adults undergoing video-assisted thoracoscopic surgery (VATS) to remove a lung lobe or a smaller anatomical part of the lung at University Medical Centre Maribor, Slovenia.
Participants will be assigned by chance to one of two groups, with 40 participants in each group:
Both groups will receive the same standard approach to pain medicines after surgery, with additional pain relief as needed.
The main question is whether adding cryoablation reduces pain during the first 72 hours after surgery. Participants will rate their pain at rest and when coughing at 6, 12, 24, 48, and 72 hours after surgery.
Researchers will also compare opioid pain medicine use, the need for additional pain relief, recovery after surgery, and side effects or complications. Follow-up assessments at 1, 3, and 6 months will evaluate persistent pain and changes in sensation, including numbness, tingling, or burning pain.
Pain after video-assisted thoracoscopic lung resection may limit deep breathing, effective coughing, and early mobilization. Intercostal nerve blocks with local anesthetics are used as part of multimodal pain management, but their duration is limited. Intercostal nerve cryoablation temporarily interrupts nerve conduction through controlled cooling and may extend postoperative pain relief. However, its additional benefit in minimally invasive lung surgery remains uncertain, and potential adverse effects include sensory disturbances and neuropathic pain.
This prospective, randomized, controlled, single-center study evaluates the additional effect of three-level intercostal nerve cryoablation when combined with five-level intercostal nerve blocks with levobupivacaine. The control group receives the same five-level levobupivacaine blocks without cryoablation. Both groups receive the same background systemic analgesic regimen and have access to rescue analgesia.
Providing the same intercostal blocks and background analgesia in both groups allows the study to assess the incremental benefit and potential harms of adding cryoablation. The study does not evaluate cryoablation as a replacement for local anesthetic nerve blocks.
The study hypothesis is that adding cryoablation will reduce early postoperative pain and opioid requirements. Pain during coughing will be evaluated alongside pain at rest to assess discomfort during an activity relevant to respiratory recovery. Analgesic consumption and recovery outcomes will complement patient-reported pain assessments.
The evaluation will consider both potential analgesic benefits and treatment-related adverse effects. Longer-term follow-up will assess persistent postoperative pain and sensory symptoms to determine whether any early improvement in pain control is accompanied by lasting benefit or unwanted effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Intercostal nerve cryoablation · Drug: Levobupivacaine
Drug: Levobupivacaine
Intraoperative cryoablation of intercostal nerves at three levels during VATS lung resection, performed using the Inomed C3 cryoanalgesia system. Cryoablation is applied at a target temperature of -80°C for 180 seconds per treated nerve. This intervention is added to five-level intercostal nerve blocks with levobupivacaine and standard systemic analgesia.
Intraoperative intercostal nerve blocks with levobupivacaine at five levels during VATS lung resection. The same concentration, volume per level, and total dose limits are used in both study groups. The experimental group additionally receives three-level intercostal nerve cryoablation, while the active comparator group receives no cryoablation.
Postoperative pain intensity at rest and during coughing measured using the Numeric Rating Scale (NRS)
Postoperative pain intensity will be assessed separately at rest and during coughing using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Scores will be recorded at each scheduled assessment and compared between the cryoablation plus levobupivacaine group and the levobupivacaine-only group. Higher scores indicate greater pain intensity.
Time frame: At 6, 12, 24, 48, and 72 hours after surgery.
Cumulative postoperative opioid consumption during hospitalization
Total dose of opioid analgesics administered during the first 72 hours after surgery, including patient-controlled analgesia and additional opioid doses. Consumption will be recorded separately by drug and route of administration.
Time frame: From the end of surgery through 72 hours after surgery.
Requirement for rescue analgesia
Proportion of participants receiving at least one dose of rescue analgesia in addition to the scheduled postoperative analgesic regimen during the first 72 hours after surgery
Time frame: Within 72 hours after surgery
Time to first postoperative mobilization
Time in hours from the end of surgery to the first documented postoperative mobilization, defined as sitting on the edge of the bed, standing, or walking. Mobilization will be monitored throughout the index hospitalization, which is expected to last an average of 7 days.
Time frame: From the end of surgery until discharge from the index hospitalization, an average of 7 days.
Postoperative length of hospital stay
Time in days from the date of surgery to discharge from the index hospitalization.
Time frame: At discharge from the index hospitalization, an average of 7 days after surgery.
Proportion of participants with postoperative complications during hospitalization
Proportion of participants experiencing at least one postoperative complication from the end of surgery until discharge from the index hospitalization. Complication types will be recorded, including pulmonary complications and adverse events potentially related to the analgesic interventions.
Time frame: From the end of surgery until discharge from the index hospitalization, an average of 7 days.
Pain intensity at 1, 3, and 6 months after surgery
Pain intensity at the surgical site will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Scores will be compared between groups at each follow-up assessment
Time frame: At 1, 3, and 6 months after surgery
Incidence of postoperative sensory disturbances
Proportion of participants reporting altered sensation in the operated chest wall, including numbness, tingling, or burning sensations. The presence and type of symptoms will be recorded at each follow-up assessment.
Time frame: At 1, 3, and 6 months after surgery
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2028; primary completion for Sep 2028, 0 months later.
Of 868 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 0 months is below that.
Counting every sponsor, half of 919 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Centre Maribor